
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Reprod. Health
Sec. HIV and STIs
Volume 7 - 2025 | doi: 10.3389/frph.2025.1499481
This article is part of the Research TopicDisclosure in Sexual and Reproductive HealthView all 5 articles
The final, formatted version of the article will be published soon.
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Parents living with HIV (PLH) face psychosocial challenges, including disclosing their HIV status to their children. Parental HIV disclosure is critical for reducing stigma, improving psychosocial wellbeing, and enhancing family cohesion. This study employed the Health Action Process Approach (HAPA) to assess the efficacy of a theory-based intervention aimed at facilitating HIV disclosure among PLH with children aged 6-15 in Guangxi, China. Data from a randomized controlled trial involving 791 PLH were analyzed using a multigroup first-order manifest Markov Chain model to investigate transitions through the pre-intention, intention, and action stages over two follow-up periods (6 and 12 months). The intervention significantly facilitated progression from pre-intention to action (OR = 3.43; 95% CI: 1.17, 10.01) but did not affect the transition from pre-intention to intention (OR = 1.02; 95% CI: 0.47, 2.20) or influence movement within the intention stage. These findings suggest the need for stage-specific interventions to enhance disclosure practices. Future research should focus on identifying psychosocial predictors of disclosure and adapt interventions to the distinct stages of the disclosure decision-making process.
Keywords: parents living with HIV, Parental HIV disclosure, Health Action Process Approach, Intervention efficacy, randomized controlled trial
Received: 26 Sep 2024; Accepted: 16 Apr 2025.
Copyright: © 2025 Li, Zhang, Da, Zhou, Shen and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xiaoming Li, University of South Carolina, Columbia, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Supplementary Material
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.